Global Information
회사소개 | 문의 | 비교리스트

D형 간염 : 파이프라인 리뷰

Hepatitis D - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 245993
페이지 정보 영문 95 Pages
가격
US $ 2,000 ₩ 2,402,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,804,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,206,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


D형 간염 : 파이프라인 리뷰 Hepatitis D - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 95 Pages

D형 간염이란 D형 간염 바이러스(HDV, 델타 바이러스)에 감염되어 간이 부어 오르는 감염증입니다. 주요 증상으로 피부·안구 황달, 관절통·복통, 구토, 식욕 부진, 권태감 등이 있습니다. 주요 위험인자에는 다량의 수혈, 정맥주사(IV) 약물·주사약 남용, 임신중 감염 등이 포함됩니다.

세계 각국의 D형 간염(Hepatitis D) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시 최신 동향, 임상시험 각 단계 제품 목록, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

목차

서론

  • 분석 범위

D형 간염 개요

치료제 개발

  • D형 간염용 파이프라인 제품 : 개요
  • 기업별 치료제
  • 대학/연구기관별 치료제
  • 개발중인 제품 목록(기업별)
  • 개발중인 제품 목록(대학/연구기관별)

D형 간염 : 치료제 평가

  • 표적별
  • 작용기서별
  • 분자 종류별

D형 간염 치료제 개발에 참여하고 있는 기업

  • Alnylam Pharmaceuticals Inc
  • Eiger BioPharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Globeimmune Inc
  • Replicor Inc
  • Rodos BioTarget GmbH
  • SomaGenics Inc
  • Spring Bank Pharmaceuticals Inc

약제 개요

휴지중인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

KSM 17.06.20

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Hepatitis D, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Hepatitis D - Pipeline by CN Bio Innovations Ltd, H1 2020
  • Hepatitis D - Pipeline by Eiger BioPharmaceuticals Inc, H1 2020
  • Hepatitis D - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
  • Hepatitis D - Pipeline by Globeimmune Inc, H1 2020
  • Hepatitis D - Pipeline by Hepion Pharmaceuticals Inc, H1 2020
  • Hepatitis D - Pipeline by Merck & Co Inc, H1 2020
  • Hepatitis D - Pipeline by MYR GmbH, H1 2020
  • Hepatitis D - Pipeline by PharmaEssentia Corp, H1 2020
  • Hepatitis D - Pipeline by Replicor Inc, H1 2020
  • Hepatitis D - Pipeline by Rodos BioTarget GmbH, H1 2020
  • Hepatitis D - Pipeline by SomaGenics Inc, H1 2020
  • Hepatitis D - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Hepatitis D, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis D - Pipeline Review, H1 2020, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape.

Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis D - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 1, 4 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Hepatitis D (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis D (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis D (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis D (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis D (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis D (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis D (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis D (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hepatitis D - Overview
    • Hepatitis D - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Hepatitis D - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hepatitis D - Companies Involved in Therapeutics Development
    • CN Bio Innovations Ltd
    • Eiger BioPharmaceuticals Inc
    • F. Hoffmann-La Roche Ltd
    • Globeimmune Inc
    • Hepion Pharmaceuticals Inc
    • Merck & Co Inc
    • MYR GmbH
    • PharmaEssentia Corp
    • Replicor Inc
    • Rodos BioTarget GmbH
    • SomaGenics Inc
  • Hepatitis D - Drug Profiles
    • Antisense RNAi Oligonucleotide for Hepatitis D - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bulevirtide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CRV-431 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GI-18000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lonafarnib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • peginterferon alfa-2a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • peginterferon lambda-1a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RBT-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REP-2139 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REP-2165 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ropeginterferon alfa-2b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Hepatitis D - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Hepatitis B and Hepatitis D Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vanitaracin A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hepatitis D - Dormant Projects
  • Hepatitis D - Product Development Milestones
    • Featured News & Press Releases
      • Nov 12, 2019: Eiger announces Peginterferon Lambda - Lonafarnib combination interim results in Hepatitis Delta Virus (HDV) infection from phase 2 LIFT study during late-breaker oral presentation at AASLD 2019
      • Nov 01, 2019: MYR Pharmaceuticals announces multiple presentations at the AASLD Meeting 2019 in Boston
      • Oct 21, 2019: Eiger announces Peginterferon Lambda combination therapy for treatment of chronic hepatitis delta virus (HDV) infection to be featured in a late-breaking oral presentation at AASLD 2019
      • Aug 20, 2019: Eiger announces FDA breakthrough therapy designation for Peginterferon Lambda for treatment of hepatitis delta virus infection
      • Jul 29, 2019: Replicor announces publication of new study examining HBsAg evolution during REP 2139
      • Jun 10, 2019: Replicor presents final REP 401 data demonstrating persistent functional cure of HBV
      • May 17, 2019: Eiger BioPharmaceuticals announces transition of Chief Operating Officer and Executive Medical Officer
      • Apr 11, 2019: Eiger Announces 36% durable virologic response at 24 weeks post-treatment with peginterferon lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019
      • Apr 04, 2019: MYR Pharmaceuticals announces presentation of final results of the MYR203 study of bulevirtide (Myrcludex) at the International Liver Congress (ILC) 2019 in Vienna
      • Apr 01, 2019: Replicor to present latest data on the beneficial impact of transaminase flares in achieving HBV functional cure at the 2019 EASL ILC meeting
      • Mar 26, 2019: Eiger BioPharmaceuticals to Participate in Conferences in April 2019
      • Mar 26, 2019: Eiger BioPharmaceuticals to participate in conferences
      • Mar 13, 2019: Eiger late-breaker oral presentation of peginterferon lambda Phase 2 LIMT study at The International Liver Congress 2019
      • Mar 05, 2019: MYR Pharma announces Grant of Promising Innovative Medicine (PIM) Designation by British MHRA for Bulevirtide (Myrcludex), the first-in-class entry inhibitor for treatment of chronic hepatitis d infections
      • Feb 06, 2019: Eiger Biopharmaceuticals announces patent protection for Lonafarnib boosted with Ritonavir for treatment of hepatitis delta virus infection in Europe and Japan
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q